Еврооблигации: Charles River Laboratories International, 4% 15mar2031, USD (FIGI RegS BBG00ZKWWF19, WKN A3L26J)
Trace-eligible, Senior Unsecured
Trace-eligible, Senior Unsecured
|
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and ...
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
|
|
|
|
|
|
|
| Following Business Day |
|
|
Откройте глобальную базу данных
1 000 000
облигаций
80 234
акций
168 394
ETF & Funds
80 000
индексов
Отслеживайте свой портфель наиболее эффективным способом
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |